Ozempic ‘microdosing’ is new weight-loss trend
Sleep apnea gets its first drug: Why US FDA approves weight loss drug for use
The United States Food and Drug Administration (FDA) has approved the weight-loss drug Tirzepatide — sold by the brand name Zepbound — for the treatment of Obstructive Sleep Apnoea (OSA), a condition in which the throat muscles sag and block air passages, resulting in difficulty breathing during sleep.
The Washington Post on MSN6d
FDA approves weight-loss drug Zepbound to treat sleep apneaThe Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...
Tryngolza (olezarsen) has been approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce trigl ...
The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
For about 25 million Americans who suffer from obstructive sleep apnea, there are various effective treatments such as CPAP breathing machines, surgery, a dental mouthpiece and even an implantable pac ...
The federal agency authorized the use of the Eli Lilly & Co. weight loss drug for “treatment of moderate to severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback